Cyndeo Wealth Partners LLC Purchases 4,450 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Cyndeo Wealth Partners LLC raised its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 35.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 16,990 shares of the company’s stock after acquiring an additional 4,450 shares during the quarter. Cyndeo Wealth Partners LLC’s holdings in EyePoint Pharmaceuticals were worth $127,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Franklin Resources Inc. raised its holdings in EyePoint Pharmaceuticals by 9.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,012,048 shares of the company’s stock worth $32,056,000 after purchasing an additional 362,399 shares during the last quarter. Patient Square Capital LP bought a new position in EyePoint Pharmaceuticals in the third quarter worth approximately $10,882,000. Geode Capital Management LLC lifted its holdings in shares of EyePoint Pharmaceuticals by 16.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company’s stock worth $9,583,000 after purchasing an additional 166,699 shares in the last quarter. Fiera Capital Corp lifted its stake in shares of EyePoint Pharmaceuticals by 0.9% in the second quarter. Fiera Capital Corp now owns 677,038 shares of the company’s stock valued at $5,890,000 after buying an additional 5,920 shares in the last quarter. Finally, Perceptive Advisors LLC boosted its stake in EyePoint Pharmaceuticals by 8.6% during the 2nd quarter. Perceptive Advisors LLC now owns 640,274 shares of the company’s stock valued at $5,570,000 after purchasing an additional 50,628 shares during the last quarter. 99.41% of the stock is owned by institutional investors.

EyePoint Pharmaceuticals Trading Down 3.3 %

Shares of EyePoint Pharmaceuticals stock opened at $8.53 on Monday. The business’s 50-day moving average price is $8.16 and its 200-day moving average price is $8.95. The firm has a market capitalization of $582.17 million, a PE ratio of -4.27 and a beta of 1.49. EyePoint Pharmaceuticals, Inc. has a 12 month low of $6.90 and a 12 month high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.06). The business had revenue of $10.52 million during the quarter, compared to the consensus estimate of $12.35 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. As a group, analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EYPT has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a report on Thursday, December 5th. Robert W. Baird decreased their target price on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating and a $33.00 target price for the company. Chardan Capital boosted their price objective on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Scotiabank initiated coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 target price on the stock. One investment analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. According to MarketBeat.com, EyePoint Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.